Scientists from Saint Peter’s University Hospital found for patients with severe COVID-19 requiring high flow nasal cannula (HFNC), triple therapy of dexamethasone, remdesivir, and baricitinib is linked to big survival benefit compared with dual therapy.
In the study, researchers examined the benefits of triple therapy of dexamethasone, remdesivir, and baricitinib compared to dual therapy of dexamethasone with remdesivir in patients with severe COVID-19.
Data were included for 191 patients with severe COVID-19, of whom 81 received triple therapy.
The researchers found a big survival benefit for patients receiving triple therapy.
There was a trend toward less requirement of mechanical ventilation for patients receiving triple versus dual therapy.
The researchers suggest people with severe COVID-19 requiring high-flow oxygen derive a strong survival benefit when treated with a triple therapy combination of dexamethasone, remdesivir, and baricitinib, in comparison to a combination of dexamethasone and remdesivir.
This is the first study focused on COVID-19 patients requiring high-flow oxygen to successfully demonstrate this finding.
For more information about COVID, please see recent studies about people who are 5 times more likely to have COVID-19 reinfection, and results showing scientists find a new treatment option for COVID-19.
The research was published in the Canadian Journal of Infectious Diseases and Medical Microbiology and conducted by Dallis Q. Ngo et al.
Copyright © 2022 Knowridge Science Report. All rights reserved.